T1	Participants 793 964	27 HER2+ breast cancer patients enrolled in a preoperative clinical trial using trastuzumab, nab-paclitaxel and carboplatin combination therapy (BrUOG BR-211B (NCT00617942
T2	Participants 968 1135	Tumor core biopsies were taken before initiation of treatment and 9-13 days after patients received "run-in" doses of either single agent trastuzumab or nab-paclitaxel
T3	Participants 1241 1363	Patients then received 18Â weeks of treatment, followed by surgery to assess pathologic response to the neoadjuvant regimen
